96 related articles for article (PubMed ID: 10422785)
1. Developmental conversion of inotropism by endothelin I and angiotensin II from positive to negative in mice.
Sekine T; Kusano H; Nishimaru K; Tanaka Y; Tanaka H; Shigenobu K
Eur J Pharmacol; 1999 Jun; 374(3):411-5. PubMed ID: 10422785
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
Shibasaki M; Fujimori A; Takanashi M; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
Eur J Pharmacol; 1997 Sep; 335(2-3):167-73. PubMed ID: 9369370
[TBL] [Abstract][Full Text] [Related]
3. Different activation of vascular mitogen-activated protein kinases in spontaneously and DOCA-salt hypertensive rats.
Kubo T; Ibusuki T; Saito E; Kambe T; Hagiwara Y
Eur J Pharmacol; 2000 Jul; 400(2-3):231-7. PubMed ID: 10988339
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs.
Shibasaki M; Fujimori A; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
Eur J Pharmacol; 1997 Sep; 335(2-3):175-84. PubMed ID: 9369371
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium.
Lenz O; Schmid B; Kilter H; La Rosée K; Flesch M; Kuhn-Regnier F; Südkamp M; Böhm M
Eur J Pharmacol; 1995 Dec; 294(1):17-27. PubMed ID: 8788412
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin AT1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin.
Ishiye M; Umemura K; Uematsu T; Nakashima M
Eur J Pharmacol; 1995 Jun; 280(1):11-7. PubMed ID: 7498249
[TBL] [Abstract][Full Text] [Related]
7. Trophic effect of angiotensin II in neonatal rat cardiomyocytes: role of endothelin-1 and non-myocyte cells.
Pönicke K; Heinroth-Hoffmann I; Becker K; Brodde OE
Br J Pharmacol; 1997 May; 121(1):118-24. PubMed ID: 9146895
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition by TAK-044 of the inotropic effects of endothelin-1 and endothelin-3.
Yomogida S; Maruya J; Norota I; Ishii K; Endoh M
Eur J Pharmacol; 2004 May; 492(2-3):217-24. PubMed ID: 15178368
[TBL] [Abstract][Full Text] [Related]
9. Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle.
Zhu Y; Yang HT; Endoh M
Am J Physiol; 1997 Jul; 273(1 Pt 2):H119-27. PubMed ID: 9249482
[TBL] [Abstract][Full Text] [Related]
10. Differential pattern of endothelin-1-induced inotropic effects in right atria and left ventricles of the human heart.
Dhein S; Giessler C; Wangemann T; Silber RE; Zerkowski HR; Brodde OE
J Cardiovasc Pharmacol; 2000 Nov; 36(5):564-9. PubMed ID: 11065215
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of cardiovascular responses induced by endothelin-1 in the perfused rat heart.
Kusumoto K; Fujiwara A; Ikeda S; Watanabe T; Fujino M
Eur J Pharmacol; 1996 Jan; 296(1):65-74. PubMed ID: 8720478
[TBL] [Abstract][Full Text] [Related]
12. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
Zhang Y; Oliver JR; Horowitz JD
Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive effect of repeatedly administered YM358, an angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats.
Yamaguchi N; Fujimoto K; Fujii T; Suzuki T; Kawashima K
Jpn J Pharmacol; 1997 Jan; 73(1):83-91. PubMed ID: 9032137
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase activity regulation role of angiotensin and endothelin systems in vascular smooth muscle cells.
Kubo T; Ibusuki T; Chiba S; Kambe T; Fukumori R
Eur J Pharmacol; 2001 Jan; 411(1-2):27-34. PubMed ID: 11137855
[TBL] [Abstract][Full Text] [Related]
15. Receptor subtypes mediating the inotropic effects and Ca(2+) signaling induced by endothelin-1 through crosstalk with norepinephrine in canine ventricular myocardium.
Chu L; Zhang JX; Norota I; Endoh M
J Pharmacol Sci; 2005 Mar; 97(3):417-28. PubMed ID: 15764840
[TBL] [Abstract][Full Text] [Related]
16. A low dose of angiotensin II increases inotropism through activation of reverse Na(+)/Ca(2+) exchange by endothelin release.
Pérez NG; Villa-Abrille MC; Aiello EA; Dulce RA; Cingolani HE; Camilión de Hurtado MC
Cardiovasc Res; 2003 Dec; 60(3):589-97. PubMed ID: 14659804
[TBL] [Abstract][Full Text] [Related]
17. Intracellular mechanisms and receptor types for endothelin-1-induced positive and negative inotropy in mouse ventricular myocardium.
Namekata I; Fujiki S; Kawakami Y; Moriwaki R; Takeda K; Kawanishi T; Takahara A; Shigenobu K; Tanaka H
Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb; 376(6):385-95. PubMed ID: 18172614
[TBL] [Abstract][Full Text] [Related]
18. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts.
Yamamoto K; Masuyama T; Sakata Y; Mano T; Nishikawa N; Kondo H; Akehi N; Kuzuya T; Miwa T; Hori M
Cardiovasc Res; 2000 Aug; 47(2):274-83. PubMed ID: 10946064
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in rats.
Oka-Akagi T; Fujimori A; Shibasaki M; Matsuda-Satoh Y; Inagaki O; Yanagisawa I
Biol Pharm Bull; 2002 Jul; 25(7):857-60. PubMed ID: 12132657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
